Merck announced results from the Phase 3 KEYNOTE-564 trial evaluating its anti-PD-1 therapy KEYTRUDA, for the adjuvant treatment of patients with renal cell carcinoma (RCC) at risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.    At the third pre-specified interim analysis (median follow-up of 57.2 months), KEYTRUDA as adjuvant therapy significantly improved overall survival (OS), the trial’s key secondary endpoint, by 38% compared to placeb...